ACH
GPCR icon

ArrowMark Colorado Holdings’s Structure Therapeutics GPCR Stock Holding History

ArrowMark Colorado Holdings’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.08M Sell
150,579
-37,616
-20% -$1.66M 0.34% 119
2026
Q1 		$9.07M Sell
188,195
-83,018
-31% -$5.68M 0.24% 126
2025
Q4 		$18.9M Sell
271,213
-51,953
-16% -$2.12M 0.42% 72
2025
Q3 		$9.05M Buy
323,166
+24,229
+8% +$483K 0.17% 144
2025
Q2 		$6.2M Buy
298,937
+53,751
+22% +$1.18M 0.11% 177
2025
Q1 		$4.24M Buy
245,186
+12,277
+5% +$301K 0.07% 184
2024
Q4 		$6.32M Sell
232,909
-8,183
-3% -$290K 0.08% 174
2024
Q3 		$10.6M Sell
241,092
-1,808
-0.7% -$69.9K 0.14% 132
2024
Q2 		$9.54M Sell
242,900
-12,349
-5% -$507K 0.11% 143
2024
Q1 		$10.9M Sell
255,249
-23,483
-8% -$990K 0.12% 136
2023
Q4 		$11.4M Buy
278,732
+228,732
+457% +$13.1M 0.13% 134
2023
Q3 		$2.52M Hold
50,000
– – 0.03% 224
2023
Q2 		$2.08M Hold
50,000
– – 0.02% 231
2023
Q1 		$1.19M Buy
+50,000
New +$1.17M 0.01% 247

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ArrowMark Colorado Holdings's GPCR Position: Q2 2026 in Review

ArrowMark Colorado Holdings reduced its Structure Therapeutics (GPCR) stake by 20% in Q2 2026, selling an estimated $1.66M and leaving 150,579 shares worth $8.08M. The position accounts for 0.34% of the portfolio, ranked #119.

ArrowMark Colorado Holdings first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $18.9M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • ArrowMark Colorado Holdings held 150,579 shares of Structure Therapeutics worth $8.08M as of Q2 2026.
  • ArrowMark Colorado Holdings sold 37,616 Structure Therapeutics shares in Q2 2026, an estimated $1.66M.
  • Structure Therapeutics made up 0.34% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #119 holding.
  • ArrowMark Colorado Holdings first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • ArrowMark Colorado Holdings's Structure Therapeutics position peaked at $18.9M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.